Current and future treatment of hyperlipidemia: the role of statins (Q40843204)

24 September 2017

1 reference

title

Current and future treatment of hyperlipidemia: the role of statins (English)

1 reference

24 September 2017

1 reference

M Farnier

1 reference

24 September 2017

J Davignon

series ordinal

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

American Journal of Cardiology

24 September 2017

published in

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

3J-10J

1 reference

Downward trend in cardiovascular mortality

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

International trends in cardiovascular diseases in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Cholesterol and mortality. 30 years of follow-up from the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

The value of lowering cholesterol after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Long-term safety and efficacy profile of simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

The primary prevention of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Design & Rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Statins do more than just lower cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Platelet function in hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Increased thromboxane biosynthesis in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effect of cholesterol on production of thromboxane b2 by platelets in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Physiological disposition of HMG-CoA-reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900423-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(98)00423-8

1 reference

24 September 2017

1 reference